Association of androgen deprivation therapy and acute kidney injury in patients with prostate cancer: a systematic review and meta-analysis of 72,980 patients.
Cancer Chemother PharmacolSep 24, 2026 (epub)
Iago Zang Pires, Alexandre Yamada Fujimura, Marília Oberto da Silva Gobbo et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the association between androgen deprivation therapy (ADT) and acute kidney injury (AKI) in 72,980 prostate cancer patients. The analysis found that ADT significantly increased the odds of AKI (OR 1.34; 95% CI 1.29-1.40; p < 0.001), particularly with GnRH agonists, which had an OR of 1.49.
Key findings
- ADT was associated with a higher occurrence of AKI (OR 1.34; 95% CI 1.29-1.40; p < 0.001).
- GnRH agonists showed a significant association with AKI risk (OR 1.49; 95% CI 1.02-2.17; p = 0.038).
- Orchiectomy was not associated with an increased risk of AKI (OR 1.1; 95% CI 0.85-1.42; p = 0.488).
- GnRH agonist therapy had a lower AKI rate compared to orchiectomy (OR 0.77; 95% CI 0.66-0.91; p = 0.001).
Why it matters
Understanding the renal risks associated with ADT is crucial for managing prostate cancer patients, as it may influence treatment decisions and monitoring strategies to mitigate potential kidney injury.